

## BIBLIOGRAPHY

1. Choi J, Kim ST, Craft J. The Pathogenesis of SLE - an Update. *Curr Opin Immunol.* 2013;24(6):651-657. doi:10.1016/j.coi.2012.10.004.The
2. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus : an update. Published online 2017:1-7. doi:10.1097/BOR.0000000000000480
3. Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CGM, Abdulahad WH. Disturbed Th1, Th2, Th17 and T reg balance in patients with systemic lupus erythematosus. *Clin Immunol.* 2011;141(2):197-204. doi:10.1016/j.clim.2011.08.005
4. Kamali AN, Noorbakhsh SM, Hamedifar H, et al. A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders. *Mol Immunol.* 2019;105(October 2018):107-115. doi:10.1016/j.molimm.2018.11.015
5. Tsanaktsi A, Solomou EE, Liossis SNC. Th1/17 cells, a subset of Th17 cells, are expanded in patients with active systemic lupus erythematosus. *Clin Immunol.* 2018;195:101-106. doi:10.1016/j.clim.2018.08.005
6. Wang D, Huang S, Yuan X, et al. The regulation of the Treg / Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. 2017;(May 2015):423-431. doi:10.1038/cmi.2015.89
7. Putra A, Ridwan FB, Putridewi AI, et al. The role of tnf- $\alpha$  induced mscs on suppressive inflammation by increasing tgf- $\beta$  and il-10. *Open Access Maced J Med Sci.* 2018;6(10):1779-1783. doi:10.3889/oamjms.2018.404
8. Infodatin-Lupus-2017.pdf.
9. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. *Expert Rev Clin Immunol.* 2018;14(12):1043-1053. doi:10.1080/1744666X.2018.1538789
10. Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. *Front Immunol.* 2015;6(OCT). doi:10.3389/fimmu.2015.00550

11. Bakshi J, Segura BT, Wincup C, Rahman A. Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. *Clin Rev Allergy Immunol*. 2018;55(3):352-367. doi:10.1007/s12016-017-8640-5
12. Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. *Clin Immunol*. Published online 2014. doi:10.1016/j.clim.2014.05.004
13. Carvalho AÉS, Sousa MRR, Alencar-Silva T, Carvalho JL, Saldanha-Araujo F. Mesenchymal stem cells immunomodulation: The road to IFN- $\gamma$  licensing and the path ahead. *Cytokine Growth Factor Rev*. 2019;47(May):32-42. doi:10.1016/j.cytogfr.2019.05.006
14. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: Adversaries and collaborators Jesse. Published online 2010:211-221. doi:10.1111/j.1749-6632.2009.05133.x.Th1
15. Haddad R, Saldanha-araujo F. Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells : What Do We Know So Far ? 2014;2014. doi:10.1155/2014/216806
16. Wang W, Yen M, Liu K, et al. Stem Cell Reports. *Stem Cell Reports*. 2015;5(3):392-404. doi:10.1016/j.stemcr.2015.07.013
17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*. 2005;105(4):1815-1822. doi:10.1182/blood-2004-04-1559
18. Cell S, Cell-material I, Sciences M. CELL -B ASED D RUG D DEVELOPMENT , SCREENING , AND TOXICOLOGY Amyotrophic Lateral Sclerosis Model Derived from Human Embryonic Stem Cells Overexpressing Mutant Superoxide Dismutase 1. Published online 2012:396-402. doi:10.5966/sctm.2012-0184
19. Tatara R, Ozaki K, Kikuchi Y, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. *Cytotherapy*. 2011;13(6):686-694. doi:10.3109/14653249.2010.542456
20. Carrión F, Nova E, Luz P, Apablaza F, Figueroa F. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the

- state of CD4 + T cell activation. *Immunol Lett.* 2011;135(1-2):10-16. doi:10.1016/j.imlet.2010.09.006
21. Zhang Z, Huang S, Wu S, et al. Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE2. *EBioMedicine.* 2019;45:341-350. doi:10.1016/j.ebiom.2019.06.016
  22. Konstantinos Tselios, Alexandros Sarantopoulos, Ionnis Gkoukouras PB. Floating Drug Delivery Systems for Eradication of Helicobacter pylori in Treatment of Peptic Ulcer Disease. *T Regul Cells Syst Lupus Erythematosus Curr Knowl Futur Prospect.* 2017;i:13. doi:10.5772/57353
  23. Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: Beyond the Th1/Th2 paradigm. *Int Immunol.* 2016;28(4):163-171. doi:10.1093/intimm/dxw006
  24. Eagar TN, Miller SD. *Helper T-Cell Subsets and Control of the Inflammatory Response.* Fifth Edit. Elsevier Ltd; 2013. doi:10.1016/B978-0-7234-3691-1.00014-3
  25. Rees F, Doherty M, Grainge MJ, Lanyon P. Original article The worldwide incidence and prevalence of systemic lupus erythematosus : a systematic review of epidemiological studies. Published online 2017:1-17. doi:10.1093/rheumatology/kex260
  26. Leffers HCB, Lange T, Collins C, Ulf-Møller CJ, Jacobsen S. The study of interactions between genome and exposome in the development of systemic lupus erythematosus. *Autoimmun Rev.* 2019;18(4):382-392. doi:10.1016/j.autrev.2018.11.005
  27. Adwan M. Eular Textbook on Rheumatic Diseases. *Saudi Med J.* 2015;36(12):476-505.
  28. Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal Stem Cell treatment for autoimmune diseases : a critical review. 2012;(56):269-277.
  29. Kusuma GD, Carthew J, Lim R, Frith JE. Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. *Stem Cells Dev.* 2017;26(9):617-631. doi:10.1089/scd.2016.0349

30. Regmi S, Pathak S, Kim JO, Yong CS, Jeong JH. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. *Eur J Cell Biol.* 2019;98(5-8):0-1. doi:10.1016/j.ejcb.2019.04.002
31. Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. *Cytotherapy.* 2015;18(2):151-159. doi:10.1016/j.jcyt.2015.11.008
32. Ma CS, Phan TG. Here, there and everywhere: T follicular helper cells on the move. *Immunology.* 2017;152(3):382-387. doi:10.1111/imm.12793
33. Eisenstein ELIM, Williams CB. The Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity. *Pediatr Res.* 2009;65(5):26-31.
34. Schmidt A, Rieger CC, Venigalla RK, et al. Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus. *Immunol Res.* 2017;65(2):551-563. doi:10.1007/s12026-017-8904-4
35. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: The ultimate identity crisis. *Front Immunol.* 2014;5(JUN):1-13. doi:10.3389/fimmu.2014.00276
36. Glenn JD. Mesenchymal Stem Cell Modulation of TH17 Cells. *Int J Stem cell Res Ther.* 2016;3(1):1-5. doi:10.23937/2469-570x/1410035
37. Mahdavi Gorabi A, Banach M, Reiner Ž, et al. The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. *J Clin Med.* 2019;8(9):1413. doi:10.3390/jcm8091413
38. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. *Trends Mol Med.* 2017;23(7):615-635. doi:10.1016/j.molmed.2017.05.006
39. Wei Y. The pathogenesis of systemic lupus erythematosus - An update. *Dermatology Res Adv.* 2014;2(6):135-160.

- doi:10.1016/j.coi.2012.10.004.The
40. Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. *Lupus*. 2015;24(4-5):351-363. doi:10.1177/0961203314556139
  41. Shah K, Lee WW, Lee SH, et al. Correction: Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. *Arthritis Res Ther*. 2010;12(3):1-10. doi:10.1186/ar2996
  42. Alunno A, Bartoloni E, Bistoni O, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new. *Clin Dev Immunol*. 2012;2012. doi:10.1155/2012/823085
  43. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. *Arch Immunol Ther Exp (Warsz)*. 2015;63(6):435-449. doi:10.1007/s00005-015-0344-z
  44. Baghaei K, Hashemi SM, Tokhanbigli S, et al. Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. *Gastroenterol Hepatol from Bed to Bench*. 2017;10(3):208-213. doi:10.22037/ghfbb.v0i0.1089
  45. Li H, Shen S, Fu H, et al. Immunomodulatory functions of mesenchymal stem cells in tissue engineering. *Stem Cells Int*. 2019;2019. doi:10.1155/2019/9671206
  46. Ikhsan R, Putra A, Munir D, Darlan DM, Suntoko B, Retno A. Mesenchymal Stem Cells Induce Regulatory T-cell Population in Human SLE. *Bangladesh J Med Sci*. 2020;19(04):743-748.
  47. Darlan DM, Munir D, Putra A, Jusuf NK. MSCs-released TGFβ1 generate CD4+CD25+Foxp3+ in T-reg cells of human SLE PBMC. *J Formos Med Assoc*. 2020;(xxxx):1-7. doi:10.1016/j.jfma.2020.06.028
  48. Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3 + regulatory T cell population during the differentiation process of Th1 and Th17 cells. *Stem Cell Res Ther*. 2013;4(3). doi:10.1186/scrt216
  49. Aksu AE, Horibe E, Sacks J, et al. Co-infusion of donor bone marrow with

- host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. *Clin Immunol.* 2008;127(3):348-358. doi:10.1016/j.clim.2008.02.003
50. Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. *Cell Mol Immunol.* 2017;14(5):423-431. doi:10.1038/cmi.2015.89
51. Terraza-aguirre C, Campos-mora M, Elizondo-vega R, et al. Mechanisms behind the Immunoregulatory Dialogue. Published online 2020.
52. Lingyun, Suna; Kentaro, Akiyamab; Huayong, Zhanga; Takayoshi, Yamazab; Yayi, Houa; Shengnan, Zhaoa; Ting Xua, Anh Leb and SS. Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus Mice and Humans. *Cell Dev Biol.* 2013;10(2):54-56. doi:10.1002/stem.68. Mesenchymal
53. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. *Immunity.* 2004;21(4):467-476. doi:10.1016/j.immuni.2004.08.018
54. Valmori D, Raffin C, Raimbaud I, Ayyoub M. Human ROR $\gamma$ t+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineagespecific polarizing factors. *Proc Natl Acad Sci U S A.* 2010;107(45):19402-19407. doi:10.1073/pnas.1008247107